Literature DB >> 19505930

Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice.

Ayumu Hirata1, Norikazu Maeda, Aki Hiuge, Toshiyuki Hibuse, Koichi Fujita, Takuya Okada, Shinji Kihara, Tohru Funahashi, Iichiro Shimomura.   

Abstract

AIMS: In obesity, chronic low-grade inflammation and overproduction of reactive oxygen species (ROS) in fat contribute to the development of metabolic syndrome. Suppression of inflammation and ROS production in fat may attenuate the metabolic syndrome. Activation of mineralocorticoid receptor (MR) promotes inflammation in heart, kidney, and vasculature via ROS generation. However, the significance of MR in fat remains elusive. Here we investigated whether MR blockade attenuates obesity-related insulin resistance and improves adipocyte dysfunction. METHODS AND
RESULTS: Obese ob/ob and db/db mice were treated with eplerenone, a MR antagonist, for 3 weeks. 3T3-L1 adipocytes were treated with aldosterone or H2O2, with and without eplerenone or MR-siRNA. High levels of MR mRNA were detected in adipose tissue of obese ob/ob and db/db mice. Eplerenone treatment significantly reduced insulin resistance, suppressed macrophage infiltration and ROS production in adipose tissues, and corrected the mRNA levels of obesity-related genes in obese mice. In 3T3-L1 adipocytes, aldosterone and H2O2 increased intracellular ROS levels and MR blockade inhibited such increases. H2O2 and aldosterone resulted in dysregulation of mRNAs of various genes related to ROS and cytokines, whereas MR blockade corrected such changes.
CONCLUSION: MR blockade attenuates obesity-related insulin resistance partly through reduction of fat ROS production, inflammatory process, and induction of cytokines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505930     DOI: 10.1093/cvr/cvp191

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  68 in total

Review 1.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

Review 2.  Cortisol dysregulation in obesity-related metabolic disorders.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

3.  Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.

Authors:  Margarita Pizarro; Nancy Solís; Pablo Quintero; Francisco Barrera; Daniel Cabrera; Pamela Rojas-de Santiago; Juan P Arab; Oslando Padilla; Juan C Roa; Han Moshage; Alexander Wree; Eugenia Inzaugarat; Ariel E Feldstein; Carlos E Fardella; Rene Baudrand; Arnoldo Riquelme; Marco Arrese
Journal:  Liver Int       Date:  2015-02-23       Impact factor: 5.828

4.  Aldosterone aggravates glucose intolerance induced by high fructose.

Authors:  Shamshad J Sherajee; Kazi Rafiq; Daisuke Nakano; Hirohito Mori; Hideki Kobara; Hirofumi Hitomi; Yoshihide Fujisawa; Hiroyuki Kobori; Tsutomu Masaki; Akira Nishiyama
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

Review 5.  Aldosterone and diabetic kidney disease.

Authors:  Young Sun Kang; Dae Ryong Cha
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

6.  Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Linda Fried; Ping Tepper; Emma Barinas-Mitchell; Molly B Conroy; Rhobert W Evans; Maria Mori Brooks; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Hypertens Res       Date:  2013-05-09       Impact factor: 3.872

Review 7.  The renin-angiotensin-aldosterone system and glucose homeostasis.

Authors:  James Matthew Luther; Nancy J Brown
Journal:  Trends Pharmacol Sci       Date:  2011-08-29       Impact factor: 14.819

Review 8.  Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.

Authors:  Jonathan G Owen; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

9.  The glucocorticoid receptor in osteoprogenitors regulates bone mass and marrow fat.

Authors:  Jessica L Pierce; Ke-Hong Ding; Jianrui Xu; Anuj K Sharma; Kanglun Yu; Natalia Del Mazo Arbona; Zuleika Rodriguez-Santos; Paul Bernard; Wendy B Bollag; Maribeth H Johnson; Mark W Hamrick; Dana L Begun; Xing M Shi; Carlos M Isales; Meghan E McGee-Lawrence
Journal:  J Endocrinol       Date:  2019-07-01       Impact factor: 4.286

10.  Production and degradation of extracellular matrix in reversible glomerular lesions in rat model of habu snake venom-induced glomerulonephritis.

Authors:  Tayo Kawazu; Tomoya Nishino; Yoko Obata; Akira Furusu; Masanobu Miyazaki; Katsushige Abe; Takehiko Koji; Shigeru Kohno
Journal:  Med Mol Morphol       Date:  2012-12-07       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.